Cytocybernetics raised a round of funding on November 19, 2018. Investors include National Institute of Mental Health.
Cytocybernetics has developed a technology to improve drug safety screening. Its product, the Cybercyte, will ensure that new drugs brought to market do not cause cardiac arrhythmias as a side effect.…
